Desitin sells global rights of Sulthiame in sleep apnea to Apnimed, Inc.
“Desitin is proud to have contributed to the ongoing clinical development of sulthiame, an investigational compound with compelling Phase 2 efficacy data and a favourable safety profile,” said Philipp Bloching, MD, Chief Executive Officer of Desitin.“
Desitin Acquires Rights on Orphan Drug in CNS for Europe
Desitin Arzneimittel GmbH has signed an exclusive License Agreement to commercialize an orphan drug being developed by AFT Pharmaceuticals, a specialist pharmaceutical company based in Auckland, New Zealand, to treat facial angiofibromas, a symptom of Tuberous Sclerosis Complex (TSC).
Desitin Arzneimittel GmbH is a European pharmaceutical company. We are specialized in sophisticated products for the therapy of neurological and psychiatric diseases. We also have affiliates in 9 European countries.
